The lymphomas: molecular pathways and novel therapeutic targets.
In recent years, several molecular mechanisms involved in promoting cancer cell survival and growth have been identified. These discoveries helped in designing and testing novel drugs that target specific cellular pathways. In this review, we focus on new molecular targets that are currently being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Wedgwood
Amanda
A
Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Pro
Barbara
B
Younes
Anas
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm / Q000627:therapeutic use; D018122:B7-1 Antigen / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D008223:Lymphoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm; D018122:B7-1 Antigen; D000069283:Rituximab